Health-care companies fell, but not by as much as the broad market, as an increase in Treasury yields whetted investor appetite for defensive issues.

The European Union is set to require Illumina to unwind its $7.1 billion acquisition of cancer-test developer Grail.

The Food and Drug Administration is narrowing the window for fast-tracks drug approvals based on preliminary evidence, spurring GSK, Roche Holdings and other drugmakers to remake plans for their drugs or pull them from the market.

Shares of Veru gained even after the biopharmaceutical company reported a wider loss and lower revenue in the last quarter of its fiscal year. 


 Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

12-05-22 1707ET